330 related articles for article (PubMed ID: 29703600)
1. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.
Touyz RM; Herrmann SMS; Herrmann J
J Am Soc Hypertens; 2018 Jun; 12(6):409-425. PubMed ID: 29703600
[TBL] [Abstract][Full Text] [Related]
2. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
Groarke JD; Choueiri TK; Slosky D; Cheng S; Moslehi J
Curr Treat Options Cardiovasc Med; 2014 Sep; 16(9):335. PubMed ID: 25099086
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Touyz RM; Herrmann J
NPJ Precis Oncol; 2018; 2():13. PubMed ID: 30202791
[TBL] [Abstract][Full Text] [Related]
4. Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.
Pucci G; Milan A; Paini A; Salvetti M; Cerasari A; Vaudo G
Expert Opin Biol Ther; 2019 May; 19(5):433-442. PubMed ID: 30888868
[TBL] [Abstract][Full Text] [Related]
5. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
[TBL] [Abstract][Full Text] [Related]
6. Hypertension in cancer patients treated with anti-angiogenic based regimens.
Wasserstrum Y; Kornowski R; Raanani P; Leader A; Pasvolsky O; Iakobishvili Z
Cardiooncology; 2015 Dec; 1(1):6. PubMed ID: 33530150
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibitor-Induced Hypertension.
Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD
Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399
[TBL] [Abstract][Full Text] [Related]
8. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
9. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830
[TBL] [Abstract][Full Text] [Related]
10. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
Bair SM; Choueiri TK; Moslehi J
Trends Cardiovasc Med; 2013 May; 23(4):104-13. PubMed ID: 23290365
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
13. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
León-Mateos L; Mosquera J; Antón Aparicio L
Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
[TBL] [Abstract][Full Text] [Related]
14. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
[TBL] [Abstract][Full Text] [Related]
15. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
19. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
20. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
